OMEICOS Therapeutics GmbH

OMEICOS Therapeutics is a Germany-based startup with a focus on developing first-in-class therapeutics based on the profound understanding of omega-3 fatty acid metabolism. The company has discovered a series of metabolically robust synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids that hold the potential to treat mitochondrial dysfunction, inflammatory, cardiovascular, and other diseases. These analogues activate cell type-specific endogenous pathways that promote organ and tissue protection. OMEICOS' small molecules are orally available and demonstrate improved biological activity and pharmacokinetic properties compared to their natural counterparts. The currently active PMD-OPTION Phase 2a clinical study is evaluating OMEICOS' lead development program, OMT-28, in patients with Primary Mitochondrial Disease.

This startup, founded in 2013, operates within the Health Care and Health and Wellness industries. Its headquarters is located in Germany, and it recently received a significant €17.00M Series C investment on 2nd November 2018.

The investors in the last investment round include Forbion, KfW, Remiges Ventures, Vesalius Biocapital, KG Investments, LLC, VC Fonds Technologie Berlin, The Falck Revocable Trust, SMS Group, SICAR, and HTGF | High-Tech Gruenderfonds.